TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25277025

Group type: EXPERIMENTAL
Intervention: Second-order control
Number of subjects: 36

Group type: COMPARATOR
Intervention: First-order control
Number of subjects: 36
Study: 22212862

Group type: EXPERIMENTAL
Intervention: Oral supplementation of Phlebodium decumanum during high-intensity exercise
Number of subjects: 0
Study: 19895618

Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lidocaine 2%
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 21
Study: 18172370

Group type: EXPERIMENTAL
Intervention: Monochromatic pulsating light
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 15221206

Group type: EXPERIMENTAL
Intervention: High-impact exercise regimen (supervised, progressive exercises three times per week plus home program for 12 months)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-impact exercise regimen
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 120
Study: 12065345

Group type: EXPERIMENTAL
Intervention: HFA-BDP, 200 to 800 microg/d (n = 354)
Number of subjects: 473

Group type: COMPARATOR
Intervention: CFC-BDP, 400 to 1,600 microg/d (n = 119)
Number of subjects: 473
Study: 9468743

Group type: EXPERIMENTAL
Intervention: Contingent reinforcement for cocaine abstinence and attendance at prenatal visits
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard multifaceted treatment including behaviorally based drug counseling and weekly prenatal visits
Number of subjects: 12
Study: 10172545

Group type: EXPERIMENTAL
Intervention: Drug supply and cost sharing system
Number of subjects: 11772

Group type: COMPARATOR
Intervention: Control district with only government drug supply
Number of subjects: 11772
Study: 2240642

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (75 micrograms)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Normal saline (5 mL)
Number of subjects: 39
Study: 365855

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31994989

Group type: EXPERIMENTAL
Intervention: Citrulline-malate (CM) supplementation (12g dextrose + 8g CM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (PLA) (12g dextrose)
Number of subjects: 28
Study: 31109368

Group type: EXPERIMENTAL
Intervention: TMQLB group 1 (0.4 ml/kg body weight 0.5% ropivacaine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TMQLB group 2 (0.6 ml/kg body weight 0.5% ropivacaine)
Number of subjects: 120

Group type: COMPARATOR
Intervention: TPVB control group (0.4 ml/kg body weight 0.5% ropivacaine at vertebra T10)
Number of subjects: 120
Study: 28779944

Group type: EXPERIMENTAL
Intervention: Yoga and working memory training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 26501785

Group type: EXPERIMENTAL
Intervention: Unprotected vaginal/anal sex at last sexual occasion (LSO)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Condom use at last sexual occasion (LSO)
Number of subjects: 480
Study: 23954912

Group type: EXPERIMENTAL
Intervention: Oral α‐methyl‐para‐tyrosine (catecholamine depletion)
Number of subjects: 28
Study: 21471564

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (vinorelbine-cisplatin)
Number of subjects: 1149
Study: 19379517

Group type: EXPERIMENTAL
Intervention: Telepsychology (in-home videoconferencing technology)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Same-Room (traditional face-to-face services)
Number of subjects: 224
Study: 17692155

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 mg, two tablets daily for 8 weeks, then one tablet daily for 4 weeks)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo (two tablets daily for 8 weeks)
Number of subjects: 122
Study: 15220243

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 11204585

Group type: EXPERIMENTAL
Intervention: Early mobilization (ambulating for > or = 4 hours per day)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Strict immobilization for 4 days
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both groups (immobilized and ambulating)
Number of subjects: 129
Study: 9708399

Group type: EXPERIMENTAL
Intervention: SQV-SGC 1200 mg three times a day for 16 weeks
Number of subjects: 171

Group type: COMPARATOR
Intervention: SQV-HGC 600 mg three times a day for 16 weeks
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: SQV-SGC
Number of subjects: 171

Group type: COMPARATOR
Intervention: SQV-HGC
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 171
Study: 1890497

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6138916

Group type: EXPERIMENTAL
Intervention: Dibenzyline 10 micrograms orally 6-8 hours after operation and again the next day about 18 hours later (total abdominal hysterectomy)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dibenzyline 10 micrograms orally 6-8 hours after operation and again the next day about 18 hours later (vaginal hysterectomy)
Number of subjects: 81
Study: 31287580

Group type: EXPERIMENTAL
Intervention: Daily full-body application of an emollient with ceramide and amino acids
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard skin care (control group)
Number of subjects: 100
Study: 27568322

Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with cisplatin and fluoropyrimidines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rilotumumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TKIs (sunitinib, sorafenib, regorafenib, apatinib)
Number of subjects: 0
Study: 26677724

Group type: EXPERIMENTAL
Intervention: Self-efficacy (SE) based intervention
Number of subjects: 52
Study: 25048952

Group type: EXPERIMENTAL
Intervention: Avatrombopag (100mg loading dose followed by 20, 40, or 80 mg/day on days 2‐7)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Avatrombopag (80 mg loading dose followed by 10 mg/day for days 2‐7, or 20mg/day for days 2‐4)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo (Cohort A)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo (Cohort B)
Number of subjects: 130
Study: 22751878

Group type: EXPERIMENTAL
Intervention: Intracranial pressure (ICP) monitoring
Number of subjects: 4667

Group type: COMPARATOR
Intervention: Expected hospital ICP monitoring rates
Number of subjects: 4667

Group type: COMPARATOR
Intervention: Observed hospital ICP monitoring rates
Number of subjects: 4667

Group type: EXPERIMENTAL
Intervention: Age 1 year and older
Number of subjects: 4667
Study: 20018286

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg/daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Simvastatin 20mg/daily
Number of subjects: 29
Study: 18600215

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg/day) at bedtime
Number of subjects: 180
Study: 16123546

Group type: EXPERIMENTAL
Intervention: Stroke Rehabilitation Unit (SRU)
Number of subjects: 178

Group type: COMPARATOR
Intervention: General Rehabilitation Ward (GRW)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Functional Independence Measure
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Stroke Impairment Assessment Set
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Cost of hospitalization
Number of subjects: 178
Study: 12714817

Group type: EXPERIMENTAL
Intervention: 5-FU (60 mg/kg body weight) for 48 hours
Number of subjects: 55

Group type: COMPARATOR
Intervention: Folinic acid (FA) (500 mg/m2) for 2 hours and 5-FU (2600 mg/m2) for 24 hours
Number of subjects: 55
Study: 10385499

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 134

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 134
Study: 9106574

Group type: EXPERIMENTAL
Intervention: PAV+CPAP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PAV
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 10
Study: 8239308

Group type: EXPERIMENTAL
Intervention: BMY 21,502 (300 mg tid)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: BMY 21,502
Number of subjects: 69
Study: 2870352

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg (doubled if not effective after 4 weeks)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (doubled if not effective after 4 weeks)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg (doubled if not effective after 4 weeks)
Number of subjects: 436
Study: 29534310

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin for 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon lambda 4 (IFNL4) CC genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CC genotype patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-CC genotype patients
Number of subjects: 0
Study: 26564169

Group type: EXPERIMENTAL
Intervention: Mild OSA patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 24827746

Group type: EXPERIMENTAL
Intervention: Bofutsushosan
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 22652101

Group type: EXPERIMENTAL
Intervention: Silver clear nylon dressing (SCND) applied from Day 1 of radiation therapy until 2 weeks after treatment completion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard skin care (sulfadiazine cream applied at the time of skin dermatitis)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Silver clear nylon dressing (SCND)
Number of subjects: 42
Study: 20590587

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.2 mg x kg(‐1) + Quinidine (CYP2D6 inhibitor)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.2 mg x kg(‐1) + Ketoconazole (CYP3A inhibitor)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.2 mg x kg(‐1) + Quinidine + Ketoconazole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18594164

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study: 16102766

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg at least 12 h before procedure)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no cervical priming agent)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 12031757

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane in N2O 4L/min and O2 2L/min (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 8% sevoflurane in O2 6L/min (Group 2)
Number of subjects: 60
Study: 10411811

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (50 mg/m²)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Injected methotrexate (50 mg/m²)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (chosen by women in phase 2)
Number of subjects: 187
Study: 7734262

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 19
Study: 1955552

Group type: EXPERIMENTAL
Intervention: Zona Drilling (ZD)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Zona Cutting (ZC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control Oocytes (Uncut)
Number of subjects: 49
Study: 6940435

Group type: EXPERIMENTAL
Intervention: High cholesterol diet (1400 mg cholesterol/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal cholesterol diet (400 mg cholesterol/day)
Number of subjects: 23
Study: 30823948

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate combined with phentolamine and nifedipine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Magnesium sulfate alone
Number of subjects: 160
Study: 29070042

Group type: EXPERIMENTAL
Intervention: A2 β‐casein
Number of subjects: 600

Group type: COMPARATOR
Intervention: Conventional milk (A1 and A2 β‐casein)
Number of subjects: 600
Study: 25741531

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training (MIT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nonexercise control group (CG)
Number of subjects: 71
Study: 24061995

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (AnSure)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 21334912

Group type: EXPERIMENTAL
Intervention: Smart suction device
Number of subjects: 58

Group type: COMPARATOR
Intervention: C.A.T.S.®
Number of subjects: 58
Study: 19571169

Group type: EXPERIMENTAL
Intervention: Dairy foods included in a moderate energy restricted diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary calcium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational or retrospective studies
Number of subjects: 0
Study: 17378189

Group type: EXPERIMENTAL
Intervention: Savvy Caregiver program (experimental group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 52
Study: 15056095

Group type: EXPERIMENTAL
Intervention: Retroflexed view
Number of subjects: 100

Group type: COMPARATOR
Intervention: Forward view
Number of subjects: 100
Study: 11216321

Group type: EXPERIMENTAL
Intervention: Imaginal and enactment instructions at testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypnotic procedures at testing
Number of subjects: 0
Study: 9725389

Group type: EXPERIMENTAL
Intervention: Vivostat fibrin sealant
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional hemostasis (control group)
Number of subjects: 24
Study: 8056993

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study: 2973219

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 44
Study: 29925472

Group type: EXPERIMENTAL
Intervention: Atorvastatin/ezetimibe combination
Number of subjects: 202

Group type: COMPARATOR
Intervention: Atorvastatin alone
Number of subjects: 202
Study: 28714170

Group type: EXPERIMENTAL
Intervention: Intramuscular magnesium sulphate (MgSO4) according to the Dhaka regimen (low dose)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intravenous magnesium sulphate (MgSO4) according to the Zuspan regimen
Number of subjects: 41
Study: 26714372

Group type: EXPERIMENTAL
Intervention: Compression during resistance exercise
Number of subjects: 25

Group type: COMPARATOR
Intervention: No compression during resistance exercise
Number of subjects: 25
Study: 24030409

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: β-blocker use
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Larger SVG diameter
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Grafting to the right coronary territory
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Low target vessel quality
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 322
Study: 20940200

Group type: EXPERIMENTAL
Intervention: VMPT-VT (bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide)
Number of subjects: 511

Group type: COMPARATOR
Intervention: VMP (bortezomib-melphalan-prednisone)
Number of subjects: 511
Study: 17884271

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 340
Study: 16023653

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: CEE plus a progestin
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: CEE with or without a progestin
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: CEE only or CEE plus a progestin
Number of subjects: 271
Study: 12546339

Group type: EXPERIMENTAL
Intervention: TAA nasal spray 110 microg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: TAA nasal spray 220 microg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: FP nasal spray 200 microg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 10789564

Group type: EXPERIMENTAL
Intervention: Aprotinin 4,000,000 KIU (group II)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Aprotinin 6,000,000 KIU (group III)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (group I)
Number of subjects: 42
Study: 8889902

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride, single oral doses up to 21.6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride, single oral doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride, higher doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride, administration with high fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride
Number of subjects: 0
Study: 1988237

Group type: EXPERIMENTAL
Intervention: Betaxolol (5 mg, 10 mg, 20 mg)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg, 50 mg, 100 mg)
Number of subjects: 140
Study: 6105762

Group type: EXPERIMENTAL
Intervention: Maprotiline (mean dose 138 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 17
Study: 31797203

Group type: EXPERIMENTAL
Intervention: Icotinib combined with local radiotherapy and subcutaneous injection of GM-CSF
Number of subjects: 42

Group type: COMPARATOR
Intervention: Icotinib (control group)
Number of subjects: 42
Study: 31853105

Group type: COMPARATOR
Intervention: Furosemide 40mg Q12hr with Metolazone 5mg Q24hr (Group 1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Furosemide 40mg Q12hr with Indapamide 2.5mg Q24hr (Group 2)
Number of subjects: 150
Study: 28470228

Group type: EXPERIMENTAL
Intervention: CRNNFA algorithm
Number of subjects: 0
Study: 25970861

Group type: EXPERIMENTAL
Intervention: SLO AF imaging
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enhanced SD-OCT en face imaging
Number of subjects: 30
Study: 23660169

Group type: EXPERIMENTAL
Intervention: Folinic acid (5 mg daily for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21799272

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) group (n=1,592)
Number of subjects: 3672

Group type: COMPARATOR
Intervention: Control group (n=2,080)
Number of subjects: 3672
Study: 19183804

Group type: EXPERIMENTAL
Intervention: iNO 20 ppm
Number of subjects: 8

Group type: COMPARATOR
Intervention: O(2) (controls)
Number of subjects: 8
Study: 18201581

Group type: EXPERIMENTAL
Intervention: Ropinirole 24-hour prolonged release 8 mg QD
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ropinirole immediate release 2.5 mg TID
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ropinirole 24-hour prolonged release (2-, 4-, and 8-mg tablets)
Number of subjects: 51
Study: 15197192

Group type: EXPERIMENTAL
Intervention: IV vinorelbine 25 mg/m(2) on days 1 and 8 plus IV epirubicin 90 mg/m(2) on day 1
Number of subjects: 387

Group type: COMPARATOR
Intervention: IV epirubicin 90 mg/m(2) on day 1
Number of subjects: 387
Study: 11431664

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator (ICD)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 802
Study: 9589642

Group type: EXPERIMENTAL
Intervention: GH plus IGF‐I
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IGF‐I
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 33
Study: 8028537

Group type: EXPERIMENTAL
Intervention: Active nicotine patch
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 313
Study: 2567126

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pancuronium (0.1 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 786309

Group type: EXPERIMENTAL
Intervention: viloxazin (n = 9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: amitriptyline (n = 10)
Number of subjects: 19
Study: 30920237

Group type: EXPERIMENTAL
Intervention: mTBI group
Number of subjects: 121

Group type: COMPARATOR
Intervention: age-matched norms
Number of subjects: 121
Study: 28624511

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy‐informed psychotherapy (CBT‐ip)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0
Study: 25280672

Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lunch cue (recalling previously eaten meal)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lunch cue/positive mood
Number of subjects: 64

Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 64

Group type: COMPARATOR
Intervention: No lunch cue
Number of subjects: 64
Study: 23601995

Group type: EXPERIMENTAL
Intervention: Endo-laparoscopic approach (self-expanding metallic stents followed by laparoscopic resection)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 48
Study: 22053775

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 190
Study: 20053325

Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with alefacept
Number of subjects: 0